Vidimar V[au] - Search Results

Year	Number of Results
2012	1
2014	2
2015	1
2016	1
2018	2
2019	1
2020	3
2021	1
2022	1
2023	0

1

Delivering a RAS protease halts tumor growth.

Vidimar V, Melnyk RA, Satchell KJF. Vidimar V, et al. Oncotarget. 2020 Sep 1;11(35):3265-3266. doi: 10.18632/oncotarget.27714. eCollection 2020 Sep 1. Oncotarget. 2020. PMID: 32934771 Free PMC article. No abstract available.

2

Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts.

Vidimar V, Park M, Stubbs CK, Ingram NK, Qiang W, Zhang S, Gursel D, Melnyk RA, Satchell KJF. Vidimar V, et al. Mol Cancer Ther. 2022 May 4;21(5):810-820. doi: 10.1158/1535-7163.MCT-21-0550. Mol Cancer Ther. 2022. PMID: 35247912

3

RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines.

Stubbs CK, Biancucci M, Vidimar V, Satchell KJF. Stubbs CK, et al. Among authors: vidimar v. Sci Rep. 2021 Sep 9;11(1):17925. doi: 10.1038/s41598-021-97422-0. Sci Rep. 2021. PMID: 34504197 Free PMC article.

4

An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth.

Vidimar V, Beilhartz GL, Park M, Biancucci M, Kieffer MB, Gius DR, Melnyk RA, Satchell KJF. Vidimar V, et al. Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):16938-16948. doi: 10.1073/pnas.2000312117. Epub 2020 Jul 2. Proc Natl Acad Sci U S A. 2020. PMID: 32616570 Free PMC article.

5

MutSignatures: an R package for extraction and analysis of cancer mutational signatures.

Fantini D, Vidimar V, Yu Y, Condello S, Meeks JJ. Fantini D, et al. Among authors: vidimar v. Sci Rep. 2020 Oct 26;10(1):18217. doi: 10.1038/s41598-020-75062-0. Sci Rep. 2020. PMID: 33106540 Free PMC article.

6

Inactivation of AKT induces cellular senescence in uterine leiomyoma.

Xu X, Lu Z, Qiang W, Vidimar V, Kong B, Kim JJ, Wei JJ. Xu X, et al. Among authors: vidimar v. Endocrinology. 2014 Apr;155(4):1510-9. doi: 10.1210/en.2013-1929. Epub 2014 Jan 29. Endocrinology. 2014. PMID: 24476133 Free PMC article.

7

The AKT/BCL-2 Axis Mediates Survival of Uterine Leiomyoma in a Novel 3D Spheroid Model.

Vidimar V, Chakravarti D, Bulun SE, Yin P, Nowak R, Wei JJ, Kim JJ. Vidimar V, et al. Endocrinology. 2018 Mar 1;159(3):1453-1462. doi: 10.1210/en.2017-03191. Endocrinology. 2018. PMID: 29381777 Free PMC article.

8

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Cerón-Camacho R, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C. Vidimar V, et al. Cancer Lett. 2019 Jan;440-441:145-155. doi: 10.1016/j.canlet.2018.09.029. Epub 2018 Oct 17. Cancer Lett. 2019. PMID: 30339780

9

Dysfunctional MnSOD leads to redox dysregulation and activation of prosurvival AKT signaling in uterine leiomyomas.

Vidimar V, Gius D, Chakravarti D, Bulun SE, Wei JJ, Kim JJ. Vidimar V, et al. Sci Adv. 2016 Nov 4;2(11):e1601132. doi: 10.1126/sciadv.1601132. eCollection 2016 Nov. Sci Adv. 2016. PMID: 27847869 Free PMC article.

10

Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy.

von Grabowiecki Y, Licona C, Palamiuc L, Abreu P, Vidimar V, Coowar D, Mellitzer G, Gaiddon C. von Grabowiecki Y, et al. Among authors: vidimar v. J Pharmacol Exp Ther. 2015 Jan;352(1):23-32. doi: 10.1124/jpet.114.216879. Epub 2014 Oct 17. J Pharmacol Exp Ther. 2015. PMID: 25326132

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results